Vimarsana
Biggest News Aggregation in the World

Page 10 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

AstraZeneca Files Legal Challenge to Some Drug-Price Provisions of IRA - Vimarsana News

AstraZeneca Files Legal Challenge to Some Drug-Price Provisions of IRA

By Will Feuer AstraZeneca said it has filed a legal challenge to certain aspects of the drug price negotiation provisions of the Inflation Reduction Act,...

AstraZeneca says Soliris and Lynparza approved in Japan - Vimarsana News

AstraZeneca says Soliris and Lynparza approved in Japan

AstraZeneca PLC on Thursday said both its Soliris and Lynparza treatments have been approved in Japan. The Cambridge-based pharmaceutical company said Soliris received approval for the treatment of...

AstraZeneca, Merck & Co say Lynparza approved in Japan - Vimarsana News

AstraZeneca, Merck & Co say Lynparza approved in Japan

AstraZeneca PLC and Merck & Co Inc on Thursday jointly said its Lynparza treatments have been approved in Japan. Merck & Co is a New Jersey, US-headquartered pharmaceutical maker. AstraZeneca is a...

Olaparib Plus Abiraterone Acetate Receives Japanese Approval for BRCA-Mutant mCRPC - Vimarsana News

Olaparib Plus Abiraterone Acetate Receives Japanese Approval for BRCA-Mutant mCRPC

The Japanese Ministry of Health, Labour, and Welfare has approved the combination of olaparib plus abiraterone acetate and prednisone or prednisolone for the treatment of adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.

AstraZeneca, Daiichi Sankyo gets Chinese nod for Enhertu as first HER2-directed therapy for patients with HER2-low metastatic breast cancer - Vimarsana News

AstraZeneca, Daiichi Sankyo gets Chinese nod for Enhertu as first HER2-directed therapy for patients with HER2-low metastatic breast cancer

Enhertu is a HER2-directed ADC.